StockpollyBeta
Get App
Popularity #369
RVMD · NASDAQ · Biotechnology

Revolution Medicines (RVMD)

Develops RAS(ON) therapeutics for KRAS-driven and broad RAS-driven solid tumors.

$192.22
vs last close−0.54 (−0.28%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue010000000000
Cost of revenue000000000550
Gross profit010000000−5−50
123181141157176216241265315357441505
Research & development108148118135152188206224263293344395
16322322242835415364101110
General & administrative16322322242835415364101110
Other expenses0000000000−50
Operating income−123−180−141−157−176−216−241−265−315−362−445−505
111925231921271710−3−9−139
Interest income111924212021252222212036
Interest expense0000000011121224
Other non-operating income0−48−25−23−19−21−27−17−21−9−4115
Income before tax−112−161−116−133−156−195−213−248−305−365−454−644
Income tax expense−40000−1000000
Net income from continuing operations−108−162−116−133−156−195−213−248−305−365−454−644
Net income−108−162−116−133−156−195−213−248−305−365−454−644
EPS, basic−$0.99−$1.14−$0.70−$0.81−$0.94−$1.13−$1.13−$1.31−$1.61−$1.90−$2.29−$3.06
EPS, diluted−$0.99−$1.14−$0.70−$0.81−$0.94−$1.13−$1.13−$1.31−$1.61−$1.90−$2.29−$3.06
Weighted average shares, basic109141165165167168188188189190198211
Weighted average shares, diluted109141165165167168188188189190198211
EBITDA−121−130−113−130−153−192−210−244−289−348−437−621
Depreciation & amortization233333444550
EBIT−123−132−116−133−156−195−213−248−294−353−442−621